October 26, 2022
The Phase 1 Healthy Volunteer Clinical Trial of KT-474
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2022
Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 25, 2022
Expression & Characterization of Novel Tissue Selective E3 Ligases
5th Annual Targeted Protein Degradation (TPD) Summit
Read More
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Liquid Tumors
Solid Tumors
Read More
August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
MYD88 Tumors
Read More
August 15, 2022
MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine
The 14th International Symposium on Mass Spectrometry in the Health and Life Sciences
Read More
July 28, 2022
Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases
3rd B&T Cell-Mediated Autoimmune Disease Drug Development
Read More
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
MYD88 Tumors
Read More
June 7, 2022
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Targeting protein degradation 3 – from discovery to the clinic (TPD3)
MYD88 Tumors
Read More
June 6, 2022
Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic
The American Society for Mass Spectrometry (ASMS) Annual Conference
Read More